deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.081 %1.0better0.35.095 %-